Výsledky vyhledávání

Akademický článek

Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin

Autor: Xiaoling Zhong, Ashok Narasimhan, Libbie M. Silverman, Andrew R. Young, Safi Shahda, Sheng Liu, Jun Wan, Yunlong Liu, Leonidas G. Koniaris, Teresa A. Zimmers

Publikováno v: Journal of Cachexia, Sarcopenia and Muscle, Vol 13, Iss 4, Pp 2146-2161 (2022)

Abstract Background Cachexia is frequent, deadly, and untreatable for patients with pancreatic ductal adenocarcinoma (PDAC). The reproductive hormone and cytokine Activin is a mediator of PDAC cachexia, and Activin receptor targeting was clinically t

Externí odkaz: https://doaj.org/article/e4c72c190e2d462b9a16bfb2a163156b

Zobrazit plný text záznamu

Akademický článek

The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy

Autor: Xiaoling Zhong, Marianne Pons, Christophe Poirier, Yanlin Jiang, Jianguo Liu, George E. Sandusky, Safi Shahda, Attila Nakeeb, C. Max Schmidt, Michael G. House, Eugene P. Ceppa, Nicholas J. Zyromski, Yunlong Liu, Guanglong Jiang, Marion E. Couch, Leonidas G. Koniaris, Teresa A. Zimmers

Publikováno v: Journal of Cachexia, Sarcopenia and Muscle, Vol 10, Iss 5, Pp 1083-1101 (2019)

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is a particularly lethal malignancy partly due to frequent, severe cachexia. Serum activin correlates with cachexia and mortality, while exogenous activin causes cachexia in mice. Methods Is

Externí odkaz: https://doaj.org/article/5279a49bd50a49ccb2019eb72a22b828

Zobrazit plný text záznamu

Akademický článek

Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study

Autor: Olumide B. Gbolahan, Yan Tong, Amikar Sehdev, Bert O’Neil, Safi Shahda

Publikováno v: BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)

Abstract Background Only a few patients with pancreatic ductal adenocarcinoma (PDAC) recurring after curative resection and peri-operative (neoadjuvant and adjuvant) therapy are included in clinical trials of metastatic PDAC. As such, there is a pauc

Externí odkaz: https://doaj.org/article/365d5a11d0c44c04a1ee5a097a9f335c

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer

Autor: Joshua K. Kays, Safi Shahda, Melissa Stanley, Teresa M. Bell, Bert H. O'Neill, Marc D. Kohli, Marion E. Couch, Leonidas G. Koniaris, Teresa A. Zimmers

Publikováno v: Journal of Cachexia, Sarcopenia and Muscle, Vol 9, Iss 4, Pp 673-684 (2018)

Abstract Background By the traditional definition of unintended weight loss, cachexia develops in ~80% of patients with pancreatic ductal adenocarcinoma (PDAC). Here, we measure the longitudinal body composition changes in patients with advanced PDAC

Externí odkaz: https://doaj.org/article/9f89d638b69540c7a93b551592c5638c

Zobrazit plný text záznamu

Akademický článek

APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-1-STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival.

Autor: Angelo A Cardoso, Yanlin Jiang, Meihua Luo, April M Reed, Safi Shahda, Ying He, Anirban Maitra, Mark R Kelley, Melissa L Fishel

Publikováno v: PLoS ONE, Vol 7, Iss 10, p e47462 (2012)

Pancreatic cancer is a largely incurable disease, and increasing evidence supports strategies targeting multiple molecular mediators of critical functions of pancreatic ductal adenocarcinoma cells. Intracellular redox state modulates the activity of

Externí odkaz: https://doaj.org/article/97d4faa79cf643f593fb6ae64175f2a0

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání